Another Week, Another Gene Therapy Buyout: Catalent Pays $1.2B for Paragon

The gene therapy boom continued this morning with yet another acquisition.

Contract drug manufacturer Catalent (NYSE: CTLT), of Somerset, NJ, has agreed to buy Paragon Bioservices for $1.2 billion, grabbing hold of a privately held developer of the viral “vectors” that gene therapy companies use to deliver their treatments.